Why the study?
Does ciprofibrate alter plasma concentrations of platelet-derived growth factor AB and lipid profiles in patients with advanced atherosclerosis and hyperlipidemia?
Does ciprofibrate alter plasma concentrations of platelet-derived growth factor AB and lipid profiles in patients with advanced atherosclerosis and hyperlipidemia?
Ciprofibrate significantly increases plasma PDGF AB levels independently of its lipid-lowering effects, which may contribute to plaque stabilization in patients with atherosclerosis.
Answers are grounded in this paper and cite their sources.
Ciprofibrate's PDGF AB elevation may affect plaque dynamics in atherosclerosis; extends fibrate pleiotropy beyond lipid effects in RCT data.
Fibrates, besides their hypolipidemic action, share alternative effects, such as decreased plasma fibrinogen and uric acid levels. Because of their complex action, additional effects have been investigated. A group of 23 patients with clinical signs of atherosclerosis and hyperlipoproteinemia was randomly allocated after a 1-month washout period and treated with either 100 mg/d of ciprofibrate or 100 mg/d of aspirin for 2 months. Patients were then treated with a combination of these two agents for the next 2 months. Ciprofibrate decreased plasma concentrations of triglycerides (-29%) and very-low-density lipoprotein cholesterol (-27%) in monotherapy and a larger reduction was observed if ciprofibrate was added to the aspirin therapy: triglycerides (-39%), very-low-density lipoprotein cholesterol (-33%), total cholesterol (-18%), low-density lipoprotein cholesterol (-17%), and increased high-density lipoprotein cholesterol (+36%). Ciprofibrate increased plasma levels of platelet-derived growth factor (PDGF) AB in both monotherapy patients (+162.9 pg/ml, +297%) and in aspirin-pretreated patients (+129.8 pg/ml, +134%); the increase of PDGF AB platelet store was significant only in aspirin-pretreated patients (+11.1 ng/ml, +51%). Aspirin in monotherapy did not modulate either plasma or platelet store of PDGF AB. Ciprofibrate did not inhibit thromboxane B 2 synthesis in platelets. Aspirin did not influence plasma thromboxane B 2 concentration at all, whereas it decreased thromboxane B 2 platelet production markedly in monotherapy (-85%) and in combination with ciprofibrate (-91%). Ciprofibrate increases PDGF AB content, which is amplified by aspirin pretreatment without correlation with its hypolipidemic action. The increase of PDGF production is suggested to participate in plaque stabilization.
No takes yet. Share an insight, caveat, or question.
Gajdoš et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: